300 related articles for article (PubMed ID: 30225627)
1. Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.
Boulanger Piette A; Hamoudi D; Marcadet L; Morin F; Argaw A; Ward L; Frenette J
Curr Osteoporos Rep; 2018 Oct; 16(5):541-553. PubMed ID: 30225627
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
[TBL] [Abstract][Full Text] [Related]
3. Altered bone-regulating myokine expression in skeletal muscle Of Duchenne muscular dystrophy mouse models.
Zhou S; Qian B; Wang L; Zhang C; Hogan MV; Li H
Muscle Nerve; 2018 Oct; 58(4):573-582. PubMed ID: 30028902
[TBL] [Abstract][Full Text] [Related]
4. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
[TBL] [Abstract][Full Text] [Related]
5. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
D'Amelio P; Isaia G; Isaia GC
J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κ B/Receptor Activator of Nuclear Factor Kappa-Β Ligand Signaling.
Ding Z; Shi H; Yang W
Pharmacology; 2019; 103(3-4):163-172. PubMed ID: 30695776
[TBL] [Abstract][Full Text] [Related]
8. Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling.
Pivonka P; Zimak J; Smith DW; Gardiner BS; Dunstan CR; Sims NA; Martin TJ; Mundy GR
J Theor Biol; 2010 Jan; 262(2):306-16. PubMed ID: 19782692
[TBL] [Abstract][Full Text] [Related]
9. RANKL Inhibition Reduces Cardiac Hypertrophy in
Marcadet L; Juracic ES; Khan N; Bouredji Z; Yagita H; Ward LM; Tupling AR; Argaw A; Frenette J
Cells; 2023 Jun; 12(11):. PubMed ID: 37296659
[TBL] [Abstract][Full Text] [Related]
10. Osteoimmunology: memorandum for rheumatologists.
Zhao L; Huang L; Zhang X
Sci China Life Sci; 2016 Dec; 59(12):1241-1258. PubMed ID: 27650950
[TBL] [Abstract][Full Text] [Related]
11. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases.
Baud'huin M; Lamoureux F; Duplomb L; Rédini F; Heymann D
Cell Mol Life Sci; 2007 Sep; 64(18):2334-50. PubMed ID: 17530461
[TBL] [Abstract][Full Text] [Related]
12. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical localization of RANK, RANKL and OPG in healthy and arthritic canine elbow joints.
Spahni AI; Schawalder P; Rothen B; Bosshardt DD; Lang N; Stoffel MH
Vet Surg; 2009 Aug; 38(6):780-6. PubMed ID: 19674422
[TBL] [Abstract][Full Text] [Related]
14. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
16. Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies.
Anandarajah AP; Schwarz EM
Adv Exp Med Biol; 2009; 649():85-99. PubMed ID: 19731622
[TBL] [Abstract][Full Text] [Related]
17. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
18. Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis.
Zhang PF; Pan L; Luo ZY; Zhao HJ; Cai SX
COPD; 2013 Dec; 10(6):650-6. PubMed ID: 23845033
[TBL] [Abstract][Full Text] [Related]
19. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
20. RANK/RANKL: regulators of immune responses and bone physiology.
Leibbrandt A; Penninger JM
Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
